Every time our body encounters a new disease-causing agent, a crucial defense system called adaptive immunity comes into play ...
MedPage Today on MSN
CAR-like T cells enhance tumor response in gastroesophageal cancer
Liu described the CAR-like T cells as cytokine-activated lymphocytes engineered with the tumor-targeting and -penetrating ...
A new multi-pronged antibody design could help immune cells receive stronger activation signals against cancer. Researchers ...
MedPage Today on MSN
CAR7 gene therapy shows promise in T-cell ALL
The use of base editing to generate universal off-the-shelf CAR T cells induced durable remissions -- up to 36 months in one ...
5don MSN
T cells gain superior memory through new reprogramming method, boosting cancer-fighting abilities
Georgetown University's Lombardi Comprehensive Cancer Center researchers have identified a new way to reprogram T cells, ...
A protein notorious for its role in Alzheimer’s disease may hold the key to supercharging the aging immune system, according to new research. Scientists have found that a byproduct of amyloid-beta ...
5don MSN
Autologous T cell therapy targeting multiple antigens shows promise in treating pancreatic cancer
A recent publication in Nature Medicine describes a novel immunotherapy targeting pancreatic cancer that has shown promising ...
While presenting this year’s Nobel Prize in Physiology or Medicine to three immunologists who discovered and characterized regulatory T cells, committee chair Olle Kämpe, M.D., Ph.D., told the ...
Data presented at ASH 2025 suggest earlier-line use of cilta-cel leads to better outcomes in multiple myeloma because patients have fitter immune systems and less exhausted T cells, improving CAR T ...
Higher levels of CD4-positive naïve T cells in patients receiving CAR T-cell therapy for multiple myeloma are associated with ...
In a phase 1 study, anti-CD7 chimeric antigen receptor (CAR) T cells induced complete remission in children and adults with relapsed or refractory T-cell acute lymphoblastic leukemia (ALL), with 82% ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results